In vitro antifungal susceptibilities and molecular typing of sequentially isolated clinical Cryptococcus neoformans strains from Croatia
Authors:
- 1 October 2011
- journal article
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 60 (10) , 1487-1495
Abstract
A collection of 48 clinical Cryptococcus neoformans isolates from Croatia was investigated retrospectively using in vitro antifungal susceptibility testing and molecular biological techniques to determine mating type and serotype by PCR and amplified fragment length polymorphism (AFLP) genotyping. These isolates were obtained from 15 patients: ten were human immunodeficiency virus (HIV)-negative (66.7 %) and five were HIV-positive (33.3 %). From five patients, only one isolate was available, whilst from the other ten patients, two to 11 isolates were isolated sequentially. Antifungal susceptibility was tested by a broth microdilution method. Serotype A (genotype AFLP1) and serotype D (genotype AFLP2) were both found in six patients (40 % each), and serotype AD (genotype AFLP3) in three (20.0 %) patients. Mating type α (n = 12; 80.0 %) predominated and α/a hybrids were identified in 20.0 % of patients diagnosed with cryptococcosis. Two AFLP genotypes of C. neoformans were isolated during a single episode from one patient. The in vitro antifungal MIC90 and susceptibility ranges for C. neoformans isolates were 0.5 µg ml−1 (range 0.031–0.5 µg ml−1) for amphotericin B, 4 µg ml−1 (range 1–4 µg ml−1) for flucytosine and fluconazole, 0.25 µg ml−1 (range 0.031–0.5 µg ml−1) for itraconazole and 0.062 µg ml−1 (range 0.031–0.25 µg ml−1) for voriconazole.Keywords
This publication has 33 references indexed in Scilit:
- Cryptococcus neoformansFatal Sepsis in a Chronic Lymphocytic Leukemia Patient Treated with Alemtuzumab: Case Report and Review of the LiteratureJournal of Chemotherapy, 2009
- Diversidad del complejo de especies Cryptococcus neoformans-Cryptococcus gattiiRevista Iberoamericana de Micologia, 2008
- Molecular typing and antifungal susceptibility of clinical sequential isolates of Cryptococcus neoformans from Sao Paulo State, BrazilFEMS Yeast Research, 2007
- Results Obtained with Various Antifungal Susceptibility Testing Methods Do Not Predict Early Clinical Outcome in Patients with CryptococcosisAntimicrobial Agents and Chemotherapy, 2006
- Cryptococcus neoformans Shows a Remarkable Genotypic Diversity in BrazilJournal of Clinical Microbiology, 2004
- Fluconazole and itraconazole susceptibility ofclinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for careJournal of Antimicrobial Chemotherapy, 2003
- Trends in Antifungal Drug Susceptibility of Cryptococcus neoformans Isolates in the United States: 1992 to 1994 and 1996 to 1998Antimicrobial Agents and Chemotherapy, 2001
- Evidence of Microevolution in a Clinical Case of Recurrent Cryptococcus neoformans MeningoencephalitisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2001
- Hybrid genotypes in the pathogenic yeast Cryptococcus neoformansMicrobiology, 2001
- Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazoleAntimicrobial Agents and Chemotherapy, 1993